Absci is trading 5.6% up at $11.72 as momentum continues for its AI-designed drug discovery pipeline and positive analyst sentiment.
- Wall Street analysts maintain a Strong Buy consensus, with several firms recently raising price targets following positive trial updates.
- The upward move follows a period of strengthened liquidity after a financing round that bolstered the company's balance sheet.
- While no fresh company-specific news was released today, the stock continues to benefit from ongoing bullish sentiment surrounding its AI-driven biotechnology platform.